

# Torben Plesner

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3516111/torben-plesner-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

4,137

citations

22

h-index

64

g-index

67

ext. papers

5,111

ext. citations

6.8

avg. IF

4.98

L-index

#	Paper	IF	Citations
62	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1319-1331	59.2	930
61	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1207-19	59.2	761
60	Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. <i>Blood</i> , <b>2016</b> , 128, 384-94	2.2	499
59	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 2104-2115	59.2	435
58	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , <b>2016</b> , 128, 37-44	2.2	272
57	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , <b>2016</b> , 127, 681-95	2.2	154
56	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. <i>Blood Advances</i> , <b>2017</b> , 1, 2105-2114	7.8	103
55	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 7498-7511	12.9	98
54	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , <b>2016</b> , 128, 1821-1828	2.2	82
53	High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2019</b> , 95, 279-289	4.6	77
52	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. <i>Blood</i> , <b>2019</b> , 134, 668-677	2.2	59
51	Daratumumab for the Treatment of Multiple Myeloma. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1228	8.4	46
50	Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. <i>Lancet Haematology</i> , <b>2020</b> , 7, e395-e407	14.6	44
49	Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX). <i>Blood</i> , <b>2016</b> , 128, 4531-4531	2.2	33
48	Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. <i>Leukemia</i> , <b>2021</b> , 35, 573-584	10.7	33
47	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , <b>2020</b> , 7, e447-e455	14.6	32
46	Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. <i>Blood</i> , <b>2016</b> , 128, 246-246	2.2	26

45	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , <b>2016</b> , 76, 853-67	12.1	26
44	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). <i>Blood</i> , <b>2018</b> , 132, LBA-2-LBA-2	2.2	25
43	Monoclonal antibodies in myeloma. <i>Clinical Advances in Hematology and Oncology</i> , <b>2015</b> , 13, 599-609	0.6	24
42	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1139-1149	2.2	23
41	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , <b>2019</b> , 3, e163	0.3	23
40	Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 921-6	5.1	20
39	Immunochemical studies of human beta 2-microglobulin. A review of recent methodological progress and clinical applications. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>1980</b> , 35, 627-37	9.3	20
38	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1582-1596	21.7	19
37	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 529-538	6.2	18
36	Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18fluorodeoxyglucose positron emission tomography in previously untreated patients. <i>Haematologica</i> , <b>2016</b> , 101, e415-e418	6.6	18
35	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. <i>Blood</i> , <b>2019</b> , 134, 1875-1875	2.2	18
34	Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study. <i>Blood</i> , <b>2017</b> , 130, 838-838	2.2	18
33	Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study. <i>Blood</i> , <b>2020</b> , 136, 24-26	2.2	17
32	Subcellular distribution of urokinase and urokinase receptor in human neutrophils determined by immunoelectron microscopy. <i>Ultrastructural Pathology</i> , <b>2000</b> , 24, 175-82	1.3	16
31	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). <i>Haematologica</i> , <b>2021</b> , 106, 1725-1732	6.6	16
30	Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1139-1149	2.2	14
29	Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8590-8590	2.2	14
28	Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3602-3612	2.2	14

27	Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment. <i>Haematologica</i> , <b>2016</b> , 101, e419-e422	6.6	12
26	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , <b>2019</b> , 186, e35-e39	4.5	10
25	Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. <i>Cells</i> , <b>2020</b> , 9,	7.9	8
24	High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action. <i>Blood</i> , <b>2016</b> , 128, 4521-4521	2.2	8
23	Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report. <i>Haematologica</i> , <b>2019</b> , 104, e432-e433	6.6	7
22	Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO). <i>Blood</i> , <b>2018</b> , 132, 2006-2006	2.2	7
21	Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 3037-3037	2.2	7
20	Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8013-8013	2.2	6
19	Clinically-suspected cast nephropathy: A retrospective, national, real-world study. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1352-1360	7.1	6
18	Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 1105-1109	4.5	6
17	Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8016-8016	2.2	5
16	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. <i>Blood</i> , <b>2021</b> ,	2.2	5
15	Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8025-8025	2.2	4
14	Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 227-237	2.2	4
13	High-dose therapy improves the bone remodelling compartment canopy coverage and bone formation in multiple myeloma. <i>British Journal of Haematology</i> , <b>2015</b> , 171, 355-65	4.5	3
12	Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8035-8035	2.2	3
11	Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 132-139	4.5	2
10	Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 705-11	5.1	2

9	Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry. <i>Blood</i> , <b>2019</b> , 134, 1849-1849	2.2	1
8	Corticosteroid tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8537-8537	2.2	1
7	Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study. <i>Blood</i> , <b>2021</b> , 138, 1667-1667	2.2	0
6	Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose. <i>Blood</i> , <b>2021</b> , 138, 1646-1646	2.2	0
5	Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma. <i>Clinical Hematology International</i> , <b>2020</b> , 2, 35-39	1.8	
4	Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. <i>Blood</i> , <b>2021</b> , 138, 4095-4095	2.2	
3	Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO). <i>Blood</i> , <b>2018</b> , 132, 1995-1995	2.2	
2	Long-Lasting Remissions for Myeloma Patients on Daratumumab Therapy from the GEN501 and GEN503 Trials. <i>Blood</i> , <b>2018</b> , 132, 3308-3308	2.2	
1	Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study. <i>Blood</i> , <b>2019</b> , 134, 5553-5553	2.2	